uniQure N.V.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Matthew Kapusta
- Full Time Employees
- 221
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Paasheuvelweg 25 Amsterdam NH Netherlands 1105 BP
- IPO Date
- Feb 5, 2014
- CIK
- 0001590560
- Website
- uniqure.com
- Similar Companies
- Business
- uniQure N.V. uniQure N.V. (NASDAQ: QURE) is a biopharmaceutical company focused on gene therapy, developing and commercializing adeno-associated virus (AAV)-based treatments for patients with severe genetic diseases including hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and cardiovascular conditions. Founded in 1998 and headquartered in Amsterdam, the Netherlands, with manufacturing in Lexington, Massachusetts, the company operates globally across the United States, Europe, and other regions, targeting rare disorders through its proprietary viral vector platform that enables potentially curative, one-time administered therapies. Its approved product, HEMGENIX (etranacogene dezaparvovec), addresses hemophilia B and is commercialized via an exclusive global licensing agreement with CSL Behring; the investigational pipeline features AMT-130 for Huntington's disease in late-stage trials with positive three-year topline data reported in 2025, AMT-260 for refractory mesial temporal lobe epilepsy with first patient dosing completed, AMT-162 for ALS, AMT-191 for Fabry disease, and cardiovascular programs in collaboration with Bristol Myers Squibb. Recent developments include a September 2025 refinancing of $50 million debt into a $175 million non-dilutive senior secured term loan facility with Hercules Capital, Inc., extending maturity to 2030 and providing up to $125 million additional funding tied to AMT-130 regulatory and financial milestones to support a potential 2026 U.S. commercial launch; third quarter 2025 financial results highlighted pipeline progress; and ongoing strategic partnerships such as the 2021 CSL Behring deal involving $500 million in payments and a 2023 royalty rights sale for up to $400 million to HealthCare Royalty and Sagard Healthcare.
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway
uniQure (QURE) Now Trades Above Golden Cross: Time to Buy?
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
uniQure Announces Pricing of Upsized $225 Million Public Offering
uniQure Announces $150 Million Proposed Public Offering
QURE Announces Initial Data on Gene therapy for Temporal Lobe Epilepsy
QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
UniQure: AMT-130's FDA Path Reaffirms My Bull Case
uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?
uniQure: FDA's Latest Stance On Huntington's BLA Sends Stock Soaring
Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End
UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency
What made uniQure stock nearly double on Wednesday?
FDA Signals uniQure Huntington Gene Therapy Data Could Back Accelerated Approval
This Biotech Stock Is Surging 66% on Surprise Good News From FDA
UniQure gets FDA green light to file for Huntington's gene therapy approval
uniQure Announces Plan for BLA Submission for AMT-130 in Huntington's Disease